etoposide phosphate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	3944	117091-64-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: etoposide phosphate etopofos etopophos	Etoposide phosphate is a prodrug that is converted to its active moiety, etoposide, by dephosphorylation. Etoposide causes the induction of DNA strand breaks by an interaction with DNA-topoisomerase II or the formation of free radicals, leading to cell cycle arrest, primarily at the G2 stage of the cell cycle, and cell death. Molecular weight: 668.54 Formula: C29H33O16P CLOGP: -0.87 LIPINSKI: 2 HAC: 16 HDO: 4 TPSA: 207.36 ALOGS: -2.97 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

etoposide phosphate
etopofos
etopophos

Etoposide phosphate is a prodrug that is converted to its active moiety, etoposide, by dephosphorylation. Etoposide causes the induction of DNA strand breaks by an interaction with DNA-topoisomerase II or the formation of free radicals, leading to cell cycle arrest, primarily at the G2 stage of the cell cycle, and cell death.

Molecular weight: 668.54
Formula: C29H33O16P
CLOGP: -0.87
LIPINSKI: 2
HAC: 16
HDO: 4
TPSA: 207.36
ALOGS: -2.97
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
S (Water solubility)	0.11 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
May 17, 1996	FDA	BRISTOL MYERS SQUIBB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dilatation intrahepatic duct acquired	95.04	43.98	15	898	671	63487438
Disease progression	78.03	43.98	37	876	122721	63365388
Venoocclusive liver disease	76.71	43.98	17	896	4818	63483291
Pancytopenia	48.87	43.98	25	888	96908	63391201

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Disease progression	66.81	39.02	42	1082	108035	34847772
Febrile bone marrow aplasia	62.67	39.02	19	1105	8190	34947617
Venoocclusive liver disease	58.94	39.02	18	1106	7948	34947859
Bone marrow failure	42.24	39.02	20	1104	29233	34926574
Septic shock	39.51	39.02	26	1098	71808	34883999

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Venoocclusive liver disease	124.16	35.87	33	1910	11738	79730707
Febrile bone marrow aplasia	93.49	35.87	27	1916	12993	79729452
Dilatation intrahepatic duct acquired	85.97	35.87	15	1928	723	79741722
Bone marrow failure	70.13	35.87	31	1912	51076	79691369
Febrile neutropenia	50.43	35.87	43	1900	230956	79511489
Disease progression	50.09	35.87	39	1904	184323	79558122
Thrombocytopenia	49.17	35.87	45	1898	265214	79477231
Encephalopathy	47.61	35.87	26	1917	67371	79675074
Septic shock	42.34	35.87	30	1913	122771	79619674
Cardiotoxicity	40.23	35.87	14	1929	12225	79730220
Product use in unapproved indication	39.74	35.87	39	1904	250320	79492125

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
FDA MoA	N0000000176	Topoisomerase Inhibitors
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:59517	DNA synthesis inhibitors
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D000972	Antineoplastic Agents, Phytogenic
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D059005	Topoisomerase II Inhibitors
MeSH PA	D059003	Topoisomerase Inhibitors
FDA EPC	N0000175609	Topoisomerase Inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Small cell carcinoma of lung	indication	254632001	DOID:5409
Malignant tumor of testis	indication	363449006	DOID:2998
Allogeneic bone marrow transplantation	off-label use	58390007
Ewing's sarcoma	off-label use	76909002	DOID:3369
Acute myeloid leukemia, disease	off-label use	91861009
Kaposi's sarcoma	off-label use	109385007
Diffuse non-Hodgkin's lymphoma, large cell	off-label use	109969005
Multiple myeloma	off-label use	109989006	DOID:9538
Hodgkin's disease	off-label use	118599009
Burkitt's lymphoma	off-label use	118617000
Non-small cell lung cancer	off-label use	254637007	DOID:3908
Osteosarcoma of bone	off-label use	307576001	DOID:3376
Neuroblastoma	off-label use	432328008	DOID:769
Testicular Germ Cell Tumor	off-label use
Ovarian Germ Cell Tumor Carcinoma	off-label use
Neuroendocrine Prostate Carcinoma	off-label use
Progressive Diffuse Large B-Cell Lymphoma	off-label use
Acute hemorrhage	contraindication	8573003
Fibrosis of lung	contraindication	51615001	DOID:3770
Metabolic acidosis	contraindication	59455009
Acute infectious disease	contraindication	63171007
Interstitial pneumonia	contraindication	64667001
Leukopenia	contraindication	84828003	DOID:615
Hypoalbuminemia	contraindication	119247004
Impaired renal function disorder	contraindication	197663003
Drug-induced hepatitis	contraindication	235876009
Anemia	contraindication	271737000	DOID:2355
Pregnancy, function	contraindication	289908002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Neutropenic disorder	contraindication	303011007	DOID:1227
Bone marrow depression	contraindication	307762000
Breastfeeding (mother)	contraindication	413712001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	1.64	acidic
pKa2	6.69	acidic
pKa3	13.08	acidic
pKa4	13.86	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
DNA topoisomerase 2-alpha	Enzyme	P11388	TOP2A_HUMAN	INHIBITOR				CHEMBL	CHEMBL

External reference:

ID	Source
4020979	VUID
N0000179127	NUI
D04107	KEGG_DRUG
4018141	VANDF
4020979	VANDF
C0059874	UMLSCUI
CHEBI:135867	CHEBI
CHEBI:4911	CHEBI
EVP	PDB_CHEM_ID
CHEMBL1200645	ChEMBL_ID
C061400	MESH_SUPPLEMENTAL_RECORD_UI
528XYJ8L1N	UNII
6918092	PUBCHEM_CID
DB00773	DRUGBANK_ID
24614	RXNORM
160598	MMSL
4209	MMSL
4709	MMSL
4710	MMSL
d00230	MMSL
d07388	MMSL
002674	NDDF
006055	NDDF
387316009	SNOMEDCT_US
426891005	SNOMEDCT_US
56928005	SNOMEDCT_US
C0015133	UMLSCUI
3835	INN_ID
36462	PUBCHEM_CID
D005047	MESH_DESCRIPTOR_UI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ETOPOPHOS	HUMAN PRESCRIPTION DRUG LABEL	1	61269-410	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	100 mg	INTRAVENOUS	NDA	18 sections
ETOPOPHOS	HUMAN PRESCRIPTION DRUG LABEL	1	61269-410	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	100 mg	INTRAVENOUS	NDA	18 sections